Dr. Mohammad Ashfaque, MD
Psychiatry (Psychiatry Physician)
At a glance
- In the NPI registry since
- 2011
Licensed in Texas since 2021, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
TX license T2109 (first issued 2021; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Quetiapine Fumarate Other prescribers in Richmond, TX | 36 |
| Sertraline Hcl Other prescribers in Richmond, TX | 30 |
| Mirtazapine Other prescribers in Richmond, TX | 24 |
| Lamotrigine Other prescribers in Richmond, TX | 22 |
| Duloxetine Hcl Other prescribers in Richmond, TX | 17 |
| Trazodone Hcl Other prescribers in Richmond, TX | 16 |
| Bupropion Xl (bupropion hcl) Other prescribers in Richmond, TX | 13 |
| Aripiprazole Other prescribers in Richmond, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 2 companies. The companies reported $295,974 in research payments for these studies, mostly to the institutions running them.
- Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
AbbVie Inc. · Completed · NCT06605599 - ITI-007-421
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie Inc. · Recruiting · NCT04777357 - ITI-007-601
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder
AbbVie Inc. - ITI-007-321
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO)
AbbVie Inc. - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO)
AbbVie Inc. - A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder
AbbVie Inc. - Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie Inc. · Recruiting · NCT06846320
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.